Parkinson's disease as multifactorial oxidative neurodegeneration: Implications for integrative management

Alternative Medicine Review

Volumn 5, Issue 6, 2000, Pages 502-529

  Kidd, P M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMANTADINE; ANTIOXIDANT; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CYTOCHROME P450; DOPAMINE; ENTACAPONE; ESTROGEN; FREE RADICAL; GLUTATHIONE; IRON; LEVACECARNINE; LEVODOPA; NEUROMELANIN; OCTACOSANOL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PERGOLIDE; PHOSPHATIDYLSERINE; POLYUNSATURATED FATTY ACID; PRAMIPEXOLE; PRIMROSE OIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; ROPINIROLE; SELEGILINE; TOLCAPONE; UBIDECARENONE;

BRAIN MITOCHONDRION; CLINICAL TRIAL; DETOXIFICATION; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DYSKINESIA; GASTROINTESTINAL TOXICITY; HALLUCINATION; HUMAN; LIVER TOXICITY; LOW CALORY DIET; METABOLIC RATE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATION; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PALLIDOTOMY; PARKINSON DISEASE; PATHOGENESIS; REVIEW; SUBSTANTIA NIGRA;

DISEASE PROGRESSION; ELECTRON TRANSPORT; HUMANS; LEVODOPA; MITOCHONDRIA; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; PARKINSON DISEASE, SECONDARY; PARKINSONIAN DISORDERS;

EID: 0034487963     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Neurological signs, aging, and the neurodegenerative syndromes
2. Pathoanatomy of Parkinson's disease
3. How common is dementia in Parkinson's disease?
4. Cardiac sympathetic denervation in Parkinson disease
5. Liver enzyme abnormalities in Parkinson's disease
6. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease
7. Postencephalitic parkinsonism - A review
8. Guam: Deadly disease dying out
9. Thalamic, pallidal, or subthalamic surgery for Parkinson's disease?
10. Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance
11. The impact of deep brain stimulation on executive function in Parkinson's disease
12. The genetics of Parkinson's disease
13. Genetic influence on the development of Parkinson's disease
14. Parkinson disease in twins
15. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis
16. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure
17. Biochemical mechanism of action of the dopaminergic neurotoxin MPTP
18. The biochemistry of free radicals
19. Natural antioxidants, first-line defense (Chapter 6)
20. Mitochondrial dysfunction - A pathogenetic factor in Parkinson's disease
21. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease
22. Origin and functional consequences of the complex I defect in Parkinson's disease
23. Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion
24. Role of mitochondria in the etiology and pathogenesis of Parkinson's disease
25. Glutathione: Systemic protectant against oxidative and free radical damage
26. Parkinson's disease: A disorder due to nigral glutathione deficiency?
27. Oxidative mechanisms in nigral cell death in Parkinson's disease
28. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
29. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: A possible contributory mechanism for neuronal degeneration in Parkinson's disease
30. Brain iron and ferritin in Parkinson's and Alzheimer's diseases
31. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration?
32. Metal-catalyzed oxidation of alpha-synuclein in the presence of copper(II) and hydrogen peroxide
33. The role of monoamine oxidase, iron-melanin interaction, and intracellular calcium in Parkinson's disease
34. Influence of neurotoxins and oxidative stress on the onset and progression of Parkinson's disease
35. Cell death mechanisms in Parkinson's disease
36. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease
37. Oxygen protecting enzymes in Parkinson's disease: Increase of superoxide dismutase-like activity
38. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation
39. Neurodegenerative disorders in humans: The role of glutathione in oxidative stress-mediated neuronal death
40. Reduced intravenous glutathione in the treatment of early Parkinson's disease
41. Motor neuron disease on Guam: Geographic and familial occurrence, 1956-85
42. Elevated levels of harman and norharman in cerebrospinal fluid of parkinsonian patients
43. Environmental factors in the etiology of Parkinson's disease
44. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: An x-ray microanalysis
45. Epidemiological study on the association between body burden mercury level and idiopathic Parkinson's disease
46. Parkinson's disease and pesticides
47. Parkinson's disease and brain levels of organochlorine pesticides
48. Do environmental toxins cause Parkinson's disease? A critical review
49. Exposure to home pesticides linked to Parkinson's disease
50. Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions
51. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
52. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease
53. TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid
54. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease
55. Elevated plasma levels of homocysteine in Parkinson's disease
56. Acute hyperhomocysteinaemia and endothelial dysfunction
57. L-3,4-dihydroxyphenylalanine (levodopa) lowers central nervous system S-adenosylmethionine concentrations in humans
58. Nigral endothelial dysfunction, homocysteine, and Parkinson's disease
59. Survival and cause of death in a cohort of patients with parkinsonism: Possible clues to etiology
60. Effects of tyrosine administration on serum biopterin in normal controls and patients with Parkinson's disease
61. Effects of oral L-tyrosine administration on CSF tyrosine and homovanillic acid levels in patients with Parkinson's disease
62. Therapeutic action of D-phenylalanine in Parkinson's disease
63. Tryptophan malabsorption in levodopa-treated parkinsonian patients
64. Levodopa and depression in Parkinsonism
65. Levodopa and L-tryptophan therapy in Parkinsonism
66. Treatment of Parkinson's disease with L-methionine
67. Sub-acute combined degeneration of the cord, dementia and parkinsonism due to an inborn error of folate metabolism
68. Niacin depletion in parkinsonian patients treated with L-dopa, benserazide and carbidopa
69. Nicotinic acid or N-methyl nicotinamide prolongs elevated brain dopa and dopamine in L-dopa treatment
70. Effect of chronic levodopa treatment on pyridoxine metabolism
71. Treatment of paralysis agitans with vitamin B6 (pyridoxine hydrochloride)
72. Use of pyridoxine hydrochloride (vitamin B6) in parkinsonism
73. Ascorbic acid in levodopa therapy
74. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease
75. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
76. Raised cerebrospinal-fluid copper concentration in Parkinson's disease
77. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease
78. Regional metal concentrations in Parkinson's disease, other chronic neurological diseases, and control brains
79. Hypothesis: Can N-acetylcysteine be beneficial in Parkinson's disease?
80. Protein intake and treatment of Parkinson's disease with levodopa
81. The effect of dietary protein on the efficacy of L-dopa: A double-blind study
82. Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease
83. Effect of daytime protein restriction on nutrient intakes of free-living Parkinson's disease patients
84. Dietary lipids and antioxidants in Parkinson's disease: A population-based, case-control study
85. Cell membranes, endothelia, and atherosclerosis - The importance of dietary fatty acid balance
86. Mercury poisoning and its potential impact on hormone regulation and aging: Preliminary observation using a new therapeutic approach
87. N-Acetylcysteine (NAC) and glutathione (GSH): Antioxidant and chemopreventive properties, with special reference to lung cancer
88. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects
89. Evening primrose oil (Efamol) in parkinsonian and other tremors
90. Effect on tumor necrosis factor alpha and interleukin 1-beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil
91. Essential fatty acids and the brain: Possible health implications
92. Octacosanol in Parkinsonism
93. Altered redox state of platelet coenzyme Q10 in Parkinson's disease
94. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients
95. Stimulation of endogenous L-dopa biosynthesis - A new principle for the therapy of Parkinson's disease
96. Nicotinamide adenine dinucleotide (NADH) - A new therapeutic approach to Parkinson's disease
97. Parenteral application of NADH in Parkinson's disease: Clinical improvement partially due to stimulation of endogenous levodopa biosynthesis
98. A review of nutrients and botanicals in the integrative management of cognitive dysfunction
99. Effect of intraventricular injection of 1-methyl-4-phenylpyridinium: Protection by acetyl-L-carnitine
100. Neurohomologous phosphatidylserine in Parkinsonian patients with associated disorders of cerebral metabolism
101. Risk for Parkinson's: Twin studies for the detection of asymptomatic subjects using (18F)6-fluorodopa PET
102. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease
103. The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins
104. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with (18F)dopa-PET
105. Is there neuroprotection in Parkinson's syndrome?
106. Neuroprotective effects of estrogens: Potential mechanisms of action
107. No NO prevents parkinsonism
108. Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats
109. Interleukin-1β enhances survival and interleukin-6 protects against MPP+ neurotoxicity in cultures of fetal rat dopaminergic neurons
110. Neuropsychological and behavioral aspects of transplants in Parkinson's disease and Huntington's disease
111. Neurogenesis in the adult human hippocampus
112. Promotion of survival and regeneration of nigral dopamine neurons in a rat model of Parkinson's disease after implantation of embryonal carcinoma-derived neurons genetically engineered to produce glial cell line-derived neurotrophic factor
113. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: Relevance to neuroprotection in Parkinson's disease